In re: Seroquel XR (Extended Release Quetiapine Fumarate) Antitrust Litigation

District Court, D. Delaware·Decided March 31, 2025·No. 1:20-cv-01076·Unknown

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE In re Seroquel XR (Extended Release Quetiapine Fumarate) Antitrust Litigation Master Docket No. 20-1076-CFC This Document Relates to: All Actions

MEMORANDUM ORDER Pending before me is Defendants’ motion pursuant to Federal Rule of Evidence 702 and Daubert v. Merrell Dow Pharms., Inc., 509 U.S. 579 (1993) to preclude Plaintiffs’ economics expert Dr. Keith Leffler from offering at trial the modeling opinions set forth in J] 13(E)-{F), 92—108 of Dr. Leffler’s Opening Expert Report and {f 2, 66—79 of his Rebuttal Expert Report. D.I. 633. I held oral argument on the motion on February 6, 2025. See generally D.I. 825. In a Memorandum Order issued on February 19, 2025 (D.I. 828), I required Dr. Leffler to testify at a hearing on March 11, 2025 about two “dispositive questions that govern this motion”: “(1) whether it was reasonable for Dr. Leffler to use in his model the same number of generic entrants regardless of whether Handa won on validity or non-infringement and (2) whether it was reasonable for him to have found that the number of expected generic entrants does

not materially change the alternative settlement entry date.” D.I. 828 at 9 (internal quotation marks omitted). Although the parties agreed at the outset of the March 11 hearing that I had correctly deemed both questions to be dispositive for purposes of deciding Defendants’ motion, 3.11.25 Tr. 9:8-19 (docketed as D.I. 834), I realize now, after further reflection, that the second question has no bearing on the admissibility of Dr. Leffler’s opinions under Rule 702(d). Dr. Leffler’s finding that the number of expected generic entrants does not materially change the alternative settlement

entry date is a conclusion or product of his economic model, not a principle or method applied by his model. Accordingly, the sole question that governs the pending motion is the first question I posed in the February 19 Memorandum Order. I have considered carefully Dr. Leffler’s March 11 testimony, counsel’s

arguments at the February 6 and March 11 hearings, and the parties’ extensive briefing (D.I. 634, D.I. 714, D.I. 769, D.I. 838, □□□ 839). The relevant factual background and legal standards are set forth in my February 19 Memorandum Order (D.I. 828), which I incorporate by reference. I. I find that the AstraZeneca forecasts identified in footnote 146 of Dr. Leffler’s Opening Report and the Handa forecasts in PTX 1178 (D.I. 835-9) and

PTX 1180 (D.I. 835-10) provided a reasonable basis for Dr. Leffler to have used in his model the same number of generic entrants—i.e., at least five entrants— regardless of whether the parties expected Handa to prevail on noninfringement, invalidity, or both defenses in the underlying patent case. Defendants do not dispute that the AstraZeneca forecasts cited in footnote 146 of Dr. Leffler’s Opening Report support his assertion in that footnote that those forecasts “impl[y] that [AstraZeneca] expected 5 or more generics to be competing after Handa’s exclusivity.” D.I. 835-2 J 103 n.146. Rather, they argue that Handa would have expected the number of generic entrants to vary depending on Handa’s expectations about the likelihoods of success of its noninfringement and invalidity defenses in the underlying patent litigation. Defendants’ logic makes perfect sense in the abstract. As I noted in my February 19 Memorandum Order, “[a] verdict in favor of Handa only on infringement would have allowed Handa—but not other generic manufacturers—to enter the market” whereas “fa] verdict in Handa’s favor on either of its invalidity defenses . . . would have opened the door for other generics to enter the market once Handa’s 180-day FDA exclusivity period had run.” D.I. 828 at 6. But in the real world, Handa was free to reject, ignore, or simply fail to appreciate that logic. And the forecasts in PTX 1178 and PTX 1180 appear on their face to show that on September 5 and 7, 201 1—that is, only weeks before the

challenged September 29, 2011 settlement—Handa expected that regardless of how it prevailed in the underlying patent case at least five generic manufacturers would enter the market following Handa’s exclusivity period. Of the Handa forecasts in the record that were made before the September 29, 2011 settlement,! the forecasts in PTX 1178 and PTX 1180 are closest in time to that date. Accordingly, it was reasonable for Dr. Leffler to assume for purposes of his economic model that, like AstraZeneca, Handa expected the same number of generic entrants—i.e., at least five—regardless of whether Handa prevailed on its noninfringement or invalidity defenses in the underlying patent case. Defendants concede that PTX 1178 and PTX 1180 are “simplified assessments of both a settlement (Case 1) and litigation (Case 2) outcome.” D.I. 838 at 7. They fault the forecasts, however, for “not even includ[ing] a Handa settlement scenario addressing the outcome of other generics’ ongoing litigations” and not “contemplat[ing] a noninfringed-but-valid outcome for Handa, despite [Dr.] Leffler’s assumption (based on Belvis) that this was the most likely scenario.” D.I. 838 at 8 (emphasis in the original). But Handa’s actual expectations about the likelihood and economic effects of the various potential outcomes of the underlying patent case did not have to be reasonable. And, in any event, alleged shortcomings in these actual (as opposed to hypothetical) forecasts

See PTX 1165 (835-8), PTX 1178, and PTX 1180.

are appropriate material for cross examination, not grounds for excluding Dr. Leffler’s opinions at trial. The forecasts’ lack of “contemplat[ion of] a noninfringed-but-valid outcome for Handa” arguably confirms—not undermines— the reasonableness of Dr. Leffler’s decision to use five or more generic entrants in his model regardless of expected litigation outcomes. II. My finding that the AstraZeneca forecasts identified in Dr. Leffler’s Opening Report and the Handa forecasts in PTX 1178 and PTX 1180 provided a reasonable basis for Dr. Leffler to hold constant the number of generic entrants (i.e., at five or more) in the application of his model resolves the pending motion. But it does not resolve whether and, if so, the extent to which, I will allow Dr. Leffler to refer to PTX 1178 and PTX 1180 at trial. Defendants argued in their post-hearing briefing that PTX 1178 and PTX 1180 “and any corresponding testimony” should be “stricken for non-disclosure.” D.I. 838 at 22. I have effectively denied that request, as I considered PTX 1178 and PTX 1180 in ruling today on Defendants’ Daubert motion. I decided it was appropriate to consider PTX 1178 and PTX 1180 for purposes of the motion because (1) they were identified in footnote 76 of Dr. Leffler’s Opening Report (albeit not for anything related to the number of generic entrants in Dr. Leffler’s model), D.I. 835-2 54

n.76; (2) Defendants asked Handa employees questions about them in depositions

Free access — add to your briefcase to read the full text and ask questions with AI

In re: Seroquel XR (Extended Release Quetiapine Fumarate) Antitrust Litigation, (D. Del. 2025).

In re: Seroquel XR (Extended Release Quetiapine Fumarate) Antitrust Litigation (In re: Seroquel XR (Extended Release Quetiapine Fumarate) Antitrust Litigation) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Daubert v. Merrell Dow Pharmaceuticals, Inc.
509 U.S. 579 (Supreme Court, 1993)